Diphenylpyraline Hydrochloride

證據等級: L5

預測適應症: 0 個

Diphenylpyraline Hydrochloride: Evaluation Incomplete — No Predictions Generated

One-Sentence Summary

Diphenylpyraline hydrochloride is a first-generation H1 antihistamine (piperidine class) historically used for allergic rhinitis, urticaria, and pruritus, though no SAHPRA-registered indication text was available in this Evidence Pack. The TxGNN model did not generate any repurposing predictions for this compound — most likely because the DrugBank ID could not be resolved, blocking knowledge graph linkage. As a result, no new indications, clinical trials, or supporting literature are available for evaluation at this time.

Quick Overview

Item	Content
Original Indication	Not retrievable — no SAHPRA registrations on file
Predicted New Indication	None — TxGNN pipeline returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A (pipeline did not complete)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline could not complete because the DrugBank ID for Diphenylpyraline Hydrochloride was not resolved, preventing knowledge graph traversal. Without a valid prediction, there is no repurposing candidate to evaluate.

To proceed, the following is needed:

[Blocking] Resolve DrugBank ID: Search DrugBank for “diphenylpyraline” (DB00679 is a candidate — verify and populate drugbank_id)
[Blocking] Re-run TxGNN prediction pipeline after DrugBank ID is confirmed
[High] Retrieve mechanism of action (MOA) via DrugBank API to support mechanistic rationale once predictions are available
[High] Download and parse any available professional information (PI) or package insert to populate safety warnings and contraindications
Verify whether any SAHPRA registration exists under alternative brand names (e.g., Lergobine, Histryl) and update licenses accordingly
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.